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Abstract
Objectives—To evaluate growth patterns of ambulatory males with Duchenne muscular 
dystrophy (DMD) treated with corticosteroids compared with ambulatory, steroid-naïlve males 
with DMD and age-matched unaffected general-population males and to test associations between 
growth and steroid treatment patterns among treated males.
Study design—Using data from the Muscular Dystrophy Surveillance, Tracking, and Research 
Network, we identified a total of 1768 height, 2246 weight, and 1755 body mass index (BMI) 
measurements between age 2 and 12 years for 324 ambulatory males who were treated with 
corticosteroids for at least 6 months. Growth curve comparisons and linear mixed-effects 
modeling, adjusted for race/ethnicity and birth year, were used to evaluate growth and steroid 
treatment patterns (age at initiation, dosing interval, duration, cumulative dose).
Results—Growth curves for ambulatory males treated with corticosteroids showed significantly 
shorter stature, heavier weight, and greater BMI compared with ambulatory, steroid-naïlve males 
with DMD and general-population US males. Adjusted linear mixed-effects models for 
ambulatory males treated with corticosteroids showed that earlier initiation, daily dosing, longer 
duration, and greater dosages predicted shorter stature with prednisone. Longer duration and 
greater dosages predicted shorter stature for deflazacort. Daily prednisone dosing predicted lighter 
weight, but longer duration, and greater dosages predicted heavier weight. Early initiation, less 
than daily dosing, longer duration, and greater doses predicted greater BMIs. Deflazacort 
predicted shorter stature, but lighter weight, compared with prednisone.
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Conclusion—Prolonged steroid use is significantly associated with short stature and heavier 
weight. Growth alterations associated with steroid treatment should be considered when making 
treatment decisions for males with DMD.
Corticosteroid (“steroid”) treatment in patients with Duchenne muscular dystrophy (DMD) 
has been shown to preserve1–4 or improve5–8 muscle strength and motor function, prolong 
independent ambulation,9–13 reduce or delay the onset of scoliosis,1,10,11,13–15 preserve 
respiratory function,1,4,16 and delay the onset of cardiomyopathy.10,16–18 The American 
Academy of Neurology has recommended treatment with steroids for males with DMD, and 
this recommendation was reiterated in the Centers for Disease Control and Prevention 
(CDC) in its supportive care guidelines for DMD.19
Excess weight gain is the most frequently reported side effect of steroid treatment1,7,10,20,21 
and is one of the most common reasons for discontinuation.22 Long-term daily use of 
corticosteroids also has been shown to slow linear growth10,16,20 and may exacerbate the 
short stature associated with DMD.3,23–25 Although many studies have summarized their 
observations of these growth-related side effects, none have reported the effects of steroid 
treatment on growth by steroid type, dosing frequency, cumulative dose, duration of steroid 
treatment, and age at initiation of steroid treatment in the same cohort of individuals. In 
short, even though the side effects of corticosteroids on growth are well known, the effect of 
corticosteroids on growth has not been quantified in sufficient detail to enable males with 
DMD and their families to make informed treatment decisions.
The objective of this analysis was to estimate the associations between steroid use and 
measures of height, weight, and body mass index (BMI) by the use of 2 separate analysis 
strategies: (1) compare growth curves for height, weight, and BMI for ambulatory males 
with DMD treated with corticosteroids with previously published height, weight, and BMI 
curves for ambulatory, steroid-naïlve males with DMD25 identified by the Muscular 
Dystrophy Surveillance, Tracking, and Research Network (MD STARnet) cohort, as well as 
to those for age-matched males from the general US male population26; and (2) estimate the 
associations between corticosteroids and each growth measure by steroid type (prednisone 
vs deflazacort), age at initiation of steroid treatment (years), dosing interval (at least daily vs 
less than daily), duration of steroid treatment (years), and cumulative dose (mg: dose × 
frequency × duration) among ambulatory males with DMD treated with corticosteroids.
Methods
The MD STARnet is a population-based surveillance system that aims to identify all 
individuals with childhood-onset DMD or Becker muscular dystrophy born between 1982 
and 2011 and who have ever resided near an MD STARnet site. Details of the surveillance 
methodology and case classification have been published previously.27,28 To summarize in 
brief, we retrospectively identified cases, starting in 2004, in Arizona, Colorado, Iowa, and 
Western New York. Georgia was added in 2005, and Hawaii was added in 2008. Annual 
medical record abstraction was completed through December 31, 2011, for those cases 
identified before 2011 and December 31, 2012, for those cases identified in 2011. Potential 
cases had to show symptoms before they turned 21 years of age. The case-finding 
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methodology used by MD STARnet was based on active review of source records in 
neuromuscular clinics, hospital discharge databases, private physician practices, service sites 
for children with special health care needs, and birth defect surveillance programs.27 Each 
participating site obtained permission for case finding and medical record abstraction either 
through institutional review board approval or by state-mandated public health reporting.
Critical diagnostic elements of each abstracted case record were reviewed independently by 
clinicians from each site and assigned by consensus a case definition category of “possible,” 
“probable,” “definite,” “asymptomatic,” or “affected female.”28 All possible cases had 
recorded clinical symptoms related to a dystrophinopathy and elevated creatine kinase. 
Probable cases also had an X-linked pedigree consistent with a dystrophinopathy. Definite 
cases also had a confirmed DMD mutation, a muscle biopsy showing absent dystrophin, or 
an X-linked pedigree and an affected family member with a DMD mutation or diagnostic 
muscle biopsy. Cases who met the criteria for definite, but did not show any clinical 
symptoms, were defined as asymptomatic. Affected females who were diagnosed with a 
dystrophinopathy before age 21 years and had a DMD mutation or diagnostic muscle biopsy 
also were ascertained.
To ensure comparability, the inclusion criteria for the analysis cohort represents that used by 
West et al25 and were limited to males with at least 1 plausible growth record between ages 
2 and 12 years, the absence of other serious medical conditions that could affect growth (eg, 
cancer, heart condition), clinical symptoms consistent with DMD, and treatment with 
corticosteroids for at least 6 months before loss of ambulation (Figure 1; available at 
www.jpeds.com). A total of 324 males, from whom 13 sibling pairs and 3 sibling triads were 
identified, comprised the analysis sample.
DMD
The following criteria were used to classify DMD in males treated with corticosteroids: (1) 
loss of ambulation before age of 16 years when treated with corticosteroids for at least 6 
months before the loss of ambulation; or (2) younger than 16 years of age at their last clinic 
visit who were still ambulating, with onset of earliest signs or symptoms before the sixth 
birthday. Clinical signs or symptoms included a positive Gower sign, abnormal gait, 
difficulty running or jumping, frequent falling, inability to keep up with peers, and gross 
motor delay or muscle weakness.
Growth Data
Weight and height data were obtained retrospectively from annual medical record 
abstraction. We excluded growth measurements collected before 6 months of cumulative 
steroid treatment (daily or intermittent regimens). We also excluded growth measurements 
collected after initiation of growth hormone therapy in the 18 males who received growth 
hormone therapy. We included growth measurements collected up to 12 years of age if still 
ambulating, or age at loss of ambulation, whichever came first, to align this analysis with the 
previously published analysis of growth in steroid-naïlve males with DMD in the MD 
STARnet.25 A total of 1768 height, 2246 weight, and 1755 BMI measurements were 
available for analyses.
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Steroid treatment was categorized according to drug type (deflazacort, prednisone), age at 
initiation, and 3 steroid treatment variables (dose interval, cumulative duration, and 
cumulative dosage). Steroid dose interval was dichotomized from recorded dosing intervals 
to “at least daily” (1) or “less than daily” (0). Cumulative duration of steroid treatment was 
calculated as a count of days during which the child was determined to have been treated 
with corticosteroids, on the basis of recorded steroid start and stop dates. The number of 
days was converted into number of years for analysis.
Cumulative dosage of corticosteroids was calculated as the frequency of steroid treatment 
multiplied by the dose of steroid multiplied by the duration of treatment and was summed 
for each reported change in steroid dose (reported as mg/kg). Each steroid treatment variable 
was calculated for prednisone and deflazacort separately.
Statistical Analyses
Two separate analysis strategies were conducted for growth curve comparisons and linear 
mixed-effects modeling. We used the same analysis cohort for both strategies. SAS 
statistical package 9.4 (SAS Institute Inc, Cary, North Carolina) was used for all analyses.
The first analysis strategy compared the growth curves for ambulatory males with DMD 
treated with corticosteroids with previously published growth curves for ambulatory, steroid-
naïve males with DMD identified by the MD STARnet,25 as well as with growth curves for 
age-matched general-population US males.26 To construct the growth curves for height, 
weight, and BMI for the ambulatory males with DMD treated with corticosteroids, we 
calculated the 10th, 25th, 50th, 75th, and 90th percentiles for height, weight, and BMI in 6-
month increments between the ages of 3.5 and 12 years (the small number of records 
collected between 2 and 3.5 years of age made growth curve generation unstable). If more 
than 1 growth measurement was available in a given 6-month increment, then those 
measurements were averaged, and the average value was used to create the growth charts. To 
produce percentile curves that could be directly compared with the previously published 
steroid-naïve growth charts for boys with DMD,25 as well as the CDC general-population 
growth charts,26 linear smoothing procedures similar to the smoothing procedures used by 
the 2000 CDC Growth Charts for the US were applied in 2 stages to the irregular plots of the 
empirical percentile values.26
Graphical comparisons with the growth charts for steroid-naïve males with DMD,25 as well 
as for the age-matched general US population males, were made to examine differences and 
similarities between the curves. Further comparison between the DMD-specific growth 
curves of males with DMD treated with corticosteroids and both the steroid-naïve males 
with DMD and the general-population growth curves was accomplished by standardizing 
our data using the CDC age-specific means and SDs and then calculating a weighted average 
of the standardized height, weight, and BMI scores across the age range.26 The resulting 
standardized variables were compared separately using t tests.
The second analysis strategy analyzed associations between growth and measures of steroid 
treatment using only those ambulatory males with DMD treated with corticosteroids. We 
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used a linear mixed-effects modeling approach, which allows for intrasubject correlation of 
repeated measures of growth measurements on each child and the age at which the growth 
measurements were collected. Separate linear mixed-effects models were run for each 
growth outcome z-score (dependent variables) and each steroid treatment variable of interest 
(independent variables). We adjusted for birth year and ethnicity, because these factors 
showed association with both the independent variables of interest and the outcomes, and 
thus may be potential confounders.
Results
Table I shows the demographic characteristics of the analysis cohort. Sixty-four percent of 
males with at least 6 months of documented steroid treatment used prednisone, 24% used 
deflazacort, and 11% had used both drugs (not concurrently) at some time between ages 2 
and 12 years. Steroid dose intervals ranged from 3 times a day to once a week. This diversity 
in dosing schedules likely reflects the treatment experience of boys with DMD in the US. 
Steroid treatment was started and stopped up to 3 times among MD STARnet males in the 
age range of interest (2-12 years of age). Eighty-five percent of males in the analysis cohort 
were still being treated with corticosteroids at age at last ambulation (or at 12 years old, if 
still ambulating). Average age at steroid initiation was 6.6 years, and average duration of 
steroid treatment before loss of ambulation or age 12 years, whichever occurred first, was 
3.2 years (Table I).
Growth Curve Analysis
The 50th percentile of the growth curves for ambulatory males with DMD who were treated 
with corticosteroids showed significantly shorter stature (P < .0001), heavier weight (P < .
0001), and greater BMI (P < .0001), compared with ambulatory, steroid-naïve males with 
DMD (Figures 2–4; Figure 4 available at www.jpeds.com). Although ambulatory males with 
DMD treated with corticosteroids have significantly greater weight on average, visual 
inspection of the growth curve (Figure 3) suggests that they also exhibited less extreme (very 
high or very low) weights than the ambulatory, steroid-naïve males with DMD. The 50th 
percentile of the growth curves for ambulatory males with DMD treated with corticosteroids 
also were significantly different from the CDC growth charts for general-population US 
males, with males with DMD treated with corticosteroids having shorter height, heavier 
weight, and greater BMI (all P values <.0001). The observed means, SDs, and selected 
percentiles for height, weight, and BMI among males with DMD treated with 
corticosteroids, age 3.5–12 years can be found in Figures 2–4.
Linear Mixed-Effects Modeling
Drug Type—Adjusted analyses comparing prednisone and deflazacort showed that 
treatment with deflazacort was significantly associated with shorter stature (P < .0001) but 
lighter weight (P = .005) compared with prednisone treatment. As a result, BMI was 
equivalent among users of prednisone and deflazacort (P = .53; Table II).
Prednisone—The adjusted linear mixed-effects model analyses of each treatment 
indicator for prednisone (age at initiation, dosing interval, duration, and cumulative dose) 
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demonstrated that, for height, later age at steroid initiation was associated with taller height 
(P < .001) whereas at-least-daily dosing (P < .001), longer duration (P < .001), and greater 
cumulative dosage (P < .001) were associated with shorter height (Table II). For weight, 
results showed at-least-daily dosing interval of prednisone was associated with lower weight 
(P < .01) but longer treatment duration (P < .01) and greater cumulative dosage (P < .001) 
were associated with greater weight. The treatment model results for BMI showed lower 
BMI when prednisone was initiated later (P < .01) and at-least-daily dosing was prescribed 
(P < .05) but greater BMI with longer duration (P < .05) and greater cumulative dose (P < .
001). There were no significant differences in cumulative dosage, duration of dosing, or age 
at last record of treatment between children that were on an “at-least-daily” vs a “less-than-
daily” dosing schedule.
As an example of how to translate these results into clinically useful numbers, an estimate of 
0.11 (Table II) means that for every year later a child begins prednisone treatment, the height 
increases by approximately 0.11 SDs per year. By referring to the CDC growth z-score 
charts (http://www.cdc.gov/growthcharts/zscore.htm) and using the height information for 8-
year-old boys, we see that this is roughly the equivalent of gaining 0.6 cm more height per 
year throughout childhood if steroid initiation is delayed 1 year. Likewise, shorter stature 
results from being treated with prednisone at least daily (roughly 1.8 cm shorter on average 
for every year of daily treatment), longer duration of use (roughly 1.05 cm for every year of 
prednisone treatment), and greater cumulative dosage (0.06 cm per g of prednisone). We 
caution, however, against attempting to make such direct calculations to predict the growth 
of any individual child, because a boy's past and current drug, dose, frequency, and duration 
all affect the growth pattern simultaneously.
Deflazacort—The adjusted linear mixed-effects analyses of each deflazacort treatment 
variable showed longer duration (P < .001) and greater cumulative dosage (P < .001) were 
associated with shorter height (Table II). Approximately 80% of boys with DMD being 
treated with deflazacort in our analysis were on an “at-least-daily” dosing schedule. For 
weight, at least daily dosing (P < .001) was associated with lower weight. For BMI, later age 
at deflazacort initiation (P < .01) and at-least-daily dosing (P < .01) were associated with 
lower BMI; longer duration (P = .03) and greater cumulative dose (P < .001) were associated 
with greater BMI (Table II).
Discussion
Using data from the population-based MD STARnet, we showed significant associations 
between steroid treatment and growth among ambulatory males with DMD who were treated 
with corticosteroids for at least 6 months. These males were shorter than ambulatory, 
steroid-naïve males with DMD, who are already shorter than males without DMD.25 
Furthermore, visual inspection of the growth curves for males with DMD treated with 
corticosteroids suggests that the average height of males with DMD becomes increasingly 
arrested as steroid treatment continues. Although short stature may be a socially undesirable 
side effect in a population that already experiences short height, it has been proposed that 
short stature may potentially confer a mechanical advantage by reducing muscle stress and 
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damage29,30 and may be one of the mechanisms by which corticosteroids prolong 
ambulation in males with DMD.31
Our findings were consistent with previous research1,7,10,20,21 showing that treatment with 
steroids may exacerbate weight gain in a population already susceptible to 
obesity.1,7,10,20,21,25,32 Excess weight gain may contribute to a variety of undesirable health 
issues, such as decreased time of independent ambulation, respiratory impairment, insulin 
resistance, complicated surgeries, aggravated bowel problems, and risk of cardiomyopathy.33 
Interestingly, males with DMD treated with corticosteroids have significantly increased 
weight on average but less extreme (both very high and very low) weights than the steroid-
naïve males with DMD, possibly because of more intense weight management of males 
treated with corticosteroids. Thus, the decision to treat with corticosteroids is complex, 
because the long-term health effects of growth alterations caused by steroid treatment must 
be considered.
Much research has been conducted to determine the right balance of benefits and harms of 
treatment with steroids. As expected, our results suggest a dose–response relationship for 
both prednisone and deflazacort, in that greater cumulative dosage of corticosteroids, as well 
as longer duration of use, were each associated with shorter stature, greater weight (for 
prednisone only), and greater BMI. Although families and medical providers may be 
tempted to lower the dose of corticosteroids to reduce side effects, a randomized controlled 
trial has shown a daily dose of 0.75 mg/kg of prednisone (an equivalent deflazacort dose 
would be 0.9 mg/kg) to be a more effective regimen than 0.3 mg/kg per day for improving 
muscle strength, and weight gain was observed at both doses.34 In addition, boys with DMD 
who have shorter stature appear to maintain independent ambulation longer,30 and a biologic 
mechanism has been proposed.29 Future studies of larger cohorts are needed to describe this 
potential relationship, so that families and clinicians can appropriately evaluate the risks and 
benefits of steroid treatment.
In an effort to maximize the benefits and minimize the harms of treatment with steroids, 
clinicians and researchers have also tested a variety of different dosing intervals.2,35–39 In 
MD STARnet, dosing intervals as frequent as 3 times a day and as infrequent as once a week 
were reported. Although our sample size was too small to test each dosing regimen 
separately, our results show that a dosing interval of at-least-daily dosing (prednisone only) 
reduces linear growth but may minimize weight gain and excess BMI. A National Institutes 
of Health–sponsored clinical trial is currently underway to determine the best steroid 
regimen.40 Approximately 64% of males with DMD who were treated with corticosteroids 
used prednisone only, 24% used deflazacort only, and 11% tried both. Although the side 
effects of the 2 drugs are similar, we did observe that deflazacort was associated with 
significantly less weight gain compared with prednisone and was associated with shorter 
stature. Other studies have supported this finding that deflazacort is associated with less 
weight gain than prednisone.14,41 There is still a lack of consensus on the most effective 
steroid type (prednisone or deflazacort), optimal dose, and dosing regimen (eg, daily vs 
intermittent administration) to maintain efficacy but minimize adverse effects.42,43
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Long-term treatment with steroids is effective at prolonging a variety of functions in males 
with DMD,44 and clinicians are initiating steroid treatment in males with DMD at younger 
ages in an effort to maximize the potential benefits. Our results suggest that earlier age at 
steroid initiation is associated with greater BMI, regardless of steroid type. Earlier age at 
initiation of prednisone also is associated with shorter stature, in agreement with a study on 
the early initiation of corticosteroids in males with DMD.45 Thus, families and clinicians 
considering steroid initiation at a young age should discuss the potential difficulties 
associated with shorter stature and greater BMI.
Strengths of this study include the classification of DMD using a standard protocol by a 
review committee consisting of neuromuscular clinicians from each site. These data are 
derived from a population-based cohort and are thus likely to be an accurate representation 
of growth attained at specific ages by ambulatory males with DMD. Furthermore, the MD 
STARnet surveillance methodology collects data longitudinally, which permits evaluation of 
growth throughout childhood. Adjustment for birth year enabled us to reduce cohort effects 
that may have been present because of the fact that clinical practice in prescribing 
corticosteroids to males with DMD has changed greatly over the past few decades, and 
children's growth in general has accelerated.46 A limitation of these data is the use of clinical 
measurements extracted retrospectively from medical records. We also relied on the medical 
record for information about steroid treatment, which may be incomplete and may have 
resulted in misclassification. We did not have sufficient detail on measures of motor status 
other than ambulation loss to be able to explore associations between steroid treatment and 
other motor function outcomes. Finally, the number of growth measurements was small at 
the younger ages because of varying age at steroid initiation, which limited the precision of 
some of the agespecific estimates.
In conclusion, our results suggest that prolonged steroid treatment may significantly alter the 
growth of males with DMD. The increased weight may cause a number of other undesirable 
side effects, and although steroid treatment often prolongs ambulation time, this effect is not 
consistent.47 The growth charts for steroid treated boys with DMD that we have provided 
should be very useful to both clinicians and families in ongoing monitoring of steroid 
treatment, as well as decisions regarding initiation of treatment. Physicians and families 
should consider the growth alterations associated with steroid treatment, and their potential 
long-term health effects, when making treatment decisions for males with DMD.
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Flowchart of exclusions to produce the analysis sample: the MD STARnet 2004-2012.
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Height in males with DMD who were treated with corticosteroids for ≥6 months compared 
with height in steroid-naïve males with DMD ages 2-12 years: the MD STARnet 2004-2012.
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Weight in males with DMD who were treated with corticosteroids for ≥6 months compared 
with weight in steroid-naïve males with DMD ages 2-12 years: the MD STARnet 
2004-2012.
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BMI in males with DMD who were treated with corticosteroids for ≥6 months compared 
with BMI in steroid-naïve males with DMD ages 2-12 years: the MD STARnet 2004-2012.
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Table I
Demographic and steroid treatment characteristics of ambulatory treatment using corticosteroids in males with 
DMD ages 2–12 years (n = 324): The MD STARnet 2004–2012
N (%) or mean (SD)
Race/ethnicity
 Non-Hispanic white 227 (70%)
 Hispanic 42 (13%)
 Black 10 (3%)
 Other 9 (3%)
 Unknown 36 (11%)
Current corticosteroid treatment at final observation (age at last ambulation or age 12 y if still ambulatory) 276 (85%)
Type of steroid used
 Prednisone 208 (64%)
  Treatment (N = 136*): at least daily 102 (80%)
  Average dosage >0.3 mg/kg/d 28 (19%)
 Deflazacort 78 (24%)
  Treatment (N = 56*): at least daily 45 (75%)
  Average dosage >0.5 mg/kg/d 15 (22%)
 Both (not concurrently) 38 (11%)
Age at steroid initiation, y 6.6 (1.8)
 Treated with prednisone only 6.6 (1.8)
 Treated with deflazacort only 6.5 (1.6)
Age at most recent visit, y 10.1 (1.7)
 Treated with prednisone only 10.0 (1.8)
 Treated with deflazacort only 10.1 (1.7)
Duration of corticosteroid use prior to ambulation loss or at age 12 if still ambulatory, y 3.2 (1.9)
 Treated with prednisone only 3.1 (1.9)
 Treated with deflazacort only 3.4 (1.8)
Weekly dose at final measurement (in those treated less than daily)
 Treated with prednisone only, mg/kg/wk 3.1 (2.0)
 Treated with deflazacort only, mg/kg/wk 2.9 (1.7)
*
Number with dosing frequency data available.
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Table II
Linear mixed-effects analyses* of corticosteroid treatment and growth among ambulatory males with DMD 
age 2–12 years (n = 324): The MD STARnet 2004–12
Height z score Weight z score BMI z score
Estimate (SE) P value Estimate (SE) P value Estimate (SE) P value
Prednisone treatment
 Age at initiation, y 0.11 (0.02) <.0001 0.02 (0.03) .35 −0.08 (0.03) .005
 At least daily dosing (vs < daily) −0.31 (0.09) .0007 −0.25 (0.08) .003 −0.19 (0.09) .04
 Duration of use, y −0.18 (0.02) <.0001 0.06 (0.02) .013 0.09 (0.03) .0005
 Cumulative dose, mg −0.00001 (3.6E-6) .0008 0.00003 (3.7E-6) <.00001 0.00002 (4.0E-6) <.0001
Deflazacort treatment
 Age at initiation, y 0.04 (0.04) .23 −0.04 (0.04) .39 −0.11 (0.03) .002
 At least daily dosing (vs < daily) −0.10 (0.13) .47 −0.64 (0.15) <.0001 −0.41 (0.13) .003
 Duration of use, y −0.23 (0.03) <.0001 −0.03 (0.04) .35 0.09 (0.03) .004
 Cumulative dose, mg −0.00002 (3.3E-6) <.0001 7.7E-7 (4.1E-6) .85 0.00001 (3.3E-6) .0008
Drug comparison
 Deflazacort vs prednisone (ref) −0.41 (0.06) <.0001 −0.20 (0.07) .005 0.04 (0.07) .53
*
Adjusted for year of birth and race/ethnicity.
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